Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Who's the Boss? Merck Names Managerial Team As Schering Merger Looms

Executive Summary

In a long-awaited move, Merck announced a managerial reorganization, placing several Schering-Plough executives in top management spots once the two companies finalize their proposed $41 billion merger later this year

You may also be interested in...

Will Saunders Bring Transformation To Forest?

The specialty pharma long has been scrutinized for its decisions regarding the patent cliff and business development. Now, a new CEO will have the chance to keep the company on its current course or mirror the transformations he’s put in motion at other companies.

Merck Vaccine President Slot Opens Up With McGlynn's Retirement

A consummate Merck insider, Margie McGlynn, announces her plans to retire, as the company prepares for its pending merger with Schering-Plough.

J&J To Seek Remicade Rights Amid Pending Schering-Plough/Merck Merger

Merck and Schering argue the merger does not constitute “change of control” for Remicade and Simponi under initial J&J agreement.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts